Literature DB >> 8589212

Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species.

C Ravanat1, M Freund, F Dol, Y Cadroy, J Roussi, F Incardona, J P Maffrand, B Boneu, L Drouet, C Legrand.   

Abstract

The aim of the present study was to investigate the reactivity of immunoreagents developed for clinical applications in humans in different animal species (hen, mouse, rat, rabbit, guinea-pig, dog, pig, sheep, baboon). Prothrombin fragment 1 + 2, thrombin-antithrombin III complex and fibrinopeptide A were tested for coagulation, platelet factor 4 and beta-thromboglobulin for platelet activation, glycoprotein IIb-IIIa, glycoprotein Ib and P-selectin for platelet membrane glycoproteins, D-dimers for fibrinolysis, thrombomodulin for activation of endothelial cells and thrombospondin and von Willebrand factor for adhesive proteins. Prothrombin fragment 1 + 2, platelet factor 4, beta-thromboglobulin and D-dimers were revealed only in baboons. Fibrinopeptide A was well detected in baboons but weakly in mice, dogs, pigs and sheep. Whereas glycoprotein IIb-IIIa was revealed on guinea-pig, dog and sheep platelets and glycoprotein Ib on rabbit and dog platelets, P-selectin and thrombomodulin were never detected. Thrombospondin was revealed in hens, mice, rats, guinea-pigs, pigs, sheep and baboons and von Willebrand factor in mice, rats, guinea-pigs, dogs, pigs, sheep and baboons. Interestingly, thrombin-antithrombin III complex (TAT) was detected in all species tested except the hen. A time- and dose-dependent increase in TAT was observed when rats, dogs or pigs were infused with thromboplastin (4.5-450 microliters/kg/h), while administration of hirudin (1 mg/kg) abolished this TAT generation. Thus, the TAT immunoassay could provide a tool for the screening of antithrombotic drugs in a number of animal species. However, the possibility of using a wider panel of human immunoreagents would appear to be restricted to baboons which display good species cross-reactivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589212     DOI: 10.1097/00001721-199507000-00012

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  7 in total

1.  Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.

Authors:  T Knudsen; A T Kristensen; T C Nichols; H Agersø; A L Jensen; M Kjalke; M Ezban; M Tranholm
Journal:  Haemophilia       Date:  2011-06-06       Impact factor: 4.287

2.  Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis.

Authors:  B Isermann; S B Hendrickson; M Zogg; M Wing; M Cummiskey; Y Y Kisanuki; M Yanagisawa; H Weiler
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Authors:  Paris Margaritis; Valder R Arruda; Majed Aljamali; Rodney M Camire; Alexander Schlachterman; Katherine A High
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

4.  Effect of First Long-Term Training on Whole Blood Count and Blood Clotting Parameters in Thoroughbreds.

Authors:  Arianna Miglio; Emanuela Falcinelli; Anna Maria Mezzasoma; Katia Cappelli; Samanta Mecocci; Paolo Gresele; Maria Teresa Antognoni
Journal:  Animals (Basel)       Date:  2021-02-09       Impact factor: 2.752

5.  Systemic coagulation parameters in mice after treatment with vascular targeting agents.

Authors:  Maike Unruh; Andrea Grunow; Claudia Gottstein
Journal:  Thromb J       Date:  2005-12-10

6.  Fibrinogen deficiency in a dog - a case report.

Authors:  Franck Jolivet; Armelle Diquélou; Catherine Trumel; Simon Privat; Olivier Dossin
Journal:  BMC Vet Res       Date:  2017-06-19       Impact factor: 2.741

7.  Thrombin-antithrombin complex measurement using a point-of-care testing device for diagnosis of disseminated intravascular coagulation in dogs.

Authors:  Kenji Rimpo; Aki Tanaka; Masayasu Ukai; Yuichi Ishikawa; Miyuki Hirabayashi; Toshihiro Shoyama
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.